Liposomal and Ethosomal Gels for the Topical Delivery of Anthralin: Preparation, Comparative Evaluation and Clinical Assessment in Psoriatic Patients

Abstract

To enhance anthralin efficacy against psoriasis and reduce its notorious side effects, it was loaded into various liposomal and ethosomal preparations. The nanocarriers were characterized for drug encapsulation efficiency, size, morphology and compatibility between various components. Optimum formulations were dispersed in various gel bases and drug release kinetics were studied. Clinical efficacy and safety of liposomal and ethosomal Pluronic®F-127 gels were evaluated in patients having psoriasis (clinicaltrials.gov identifier is NCT03348462). Safety was assessed by recording various adverse events. Drug encapsulation efficiency ≥97.2% and ≥77% were obtained for liposomes and ethosomes, respectively. Particle sizes of 116 to 199 nm and 146 to 381 nm were observed for liposomes and ethosomes, respectively. Fourier-Transform infrared (FT-IR) spectroscopy and differential scanning calorimetry (DSC) studies confirmed the absence of interaction between anthralin and various nanocarrier components. Tested gel bases showed excellent ability to sustain drug release. At baseline, the patients had a median Psoriasis Area and Severity Index (PASI) of 3.4 for liposomes and 3.6 for ethosomes without significant difference. After treatment, mean PASI change was −68.66% and −81.84% for liposomes and ethosomes, respectively with a significant difference in favor of ethosomes. No adverse effects were detected in both groups. Anthralin ethosomes could be considered as a potential treatment of psoriasis.

<p>Formulation of Nanospanlastics as a Promising Approach for ‎Improving the Topical Delivery of a Natural Leukotriene Inhibitor (3-‎Acetyl-11-Keto-β-Boswellic Acid): Statistical Optimization, in vitro ‎Characterization, and ex vivo Permeation Study</p>

“…Minor shifting and reduced intensity of the characteristic peaks of AKBA may be attributable to the formation of hydrogen bonds, Van der Wall forces, or dipole interactions between AKBA and other excipients increasing both the encapsulation of AKBA and the stability of the nano-vesicles. 38 These findings are in accordance with Fathalla et al 75 who reported the absence of interactions between the drug and other ingredients of the Anthralin-loaded ethosomal formulations according to the FTIR spectrum that displayed the characteristic peaks of both drug and ‎excipients with a little shift.…”

Quality by Design for Development, Optimization and Characterization of Brucine Ethosomal Gel for Skin Cancer Delivery

“…Definitely, this indicated synergistic effect of ethanol on the drug permeation across the skin, which could be returned to its effective role as a penetration enhancer [ 33 ]. In addition to the lipid-softening effect of ethanol that facilitate the penetration of the drug and improve the permeation as well [ 34 ]. In view of this, the skin permeation is affected by varying the concentration of phospholipid and ethanol [ 35 , 36 ].…”

Epigallocatechin-3-Gallate-Loaded Gold Nanoparticles: Preparation and Evaluation of Anticancer Efficacy in Ehrlich Tumor-Bearing Mice

“…This is a commonly observed behavior for nanoparticles due to the dry status of nanoparticles used in TEM measurements, which probably results in nanoparticle shrinkage. In contrast, the size obtained by DLS represents hydrated nanoparticles in solution, which explains their bigger size [35,36].…”

“…Furthermore, the potential of a given nanocarrier clinical translation is higher for those having high drug loading capacity since this minimizes the concentration of nanocarrier needed to achieve a clinically relevant drug concentration. A lower nanocarrier concentration not only limits the burden on the body to metabolize and excrete these chemicals, but also improves the colloidal stability of nanocarriers [35,48].…”